RJA
SRPT icon

Raymond James & Associates’s Sarepta Therapeutics SRPT Stock Holding History

Raymond James & Associates’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$3.21M Buy
25,713
+4,065
+19% +$562K ﹤0.01% 1928
2024
Q2 		$3.42M Buy
21,648
+8,992
+71% +$1.16M ﹤0.01% 1842
2024
Q1 		$1.64M Buy
12,656
+2,857
+29% +$350K ﹤0.01% 2291
2023
Q4 		$945K Sell
9,799
-539
-5% -$51.7K ﹤0.01% 2548
2023
Q3 		$1.25M Sell
10,338
-2,817
-21% -$318K ﹤0.01% 2312
2023
Q2 		$1.51M Sell
13,155
-182
-1% -$23.5K ﹤0.01% 2237
2023
Q1 		$1.84M Buy
13,337
+1,659
+14% +$215K ﹤0.01% 2084
2022
Q4 		$1.51M Sell
11,678
-2,466
-17% -$286K ﹤0.01% 2178
2022
Q3 		$1.56M Sell
14,144
-148
-1% -$14.9K ﹤0.01% 2123
2022
Q2 		$1.07M Buy
14,292
+154
+1% +$11.3K ﹤0.01% 2387
2022
Q1 		$1.1M Buy
14,138
+522
+4% +$40K ﹤0.01% 2525
2021
Q4 		$1.23M Buy
13,616
+5,675
+71% +$485K ﹤0.01% 2486
2021
Q3 		$734K Sell
7,941
-132
-2% -$10.2K ﹤0.01% 2780
2021
Q2 		$628K Sell
8,073
-383
-5% -$29K ﹤0.01% 2921
2021
Q1 		$630K Sell
8,456
-27,526
-76% -$2.54M ﹤0.01% 2848
2020
Q4 		$6.13M Buy
35,982
+2,538
+8% +$376K 0.01% 1224
2020
Q3 		$4.7M Buy
33,444
+10,176
+44% +$1.55M 0.01% 1267
2020
Q2 		$3.73M Buy
23,268
+1,550
+7% +$211K 0.01% 1366
2020
Q1 		$2.12M Sell
21,718
-4,135
-16% -$473K ﹤0.01% 1530
2019
Q4 		$3.34M Buy
25,853
+2,470
+11% +$249K ﹤0.01% 1521
2019
Q3 		$1.76M Buy
23,383
+5,150
+28% +$608K ﹤0.01% 1852
2019
Q2 		$2.77M Buy
18,233
+628
+4% +$76.3K ﹤0.01% 1598
2019
Q1 		$2.1M Buy
17,605
+1,667
+10% +$214K ﹤0.01% 1737
2018
Q4 		$1.74M Sell
15,938
-7,296
-31% -$912K ﹤0.01% 1747
2018
Q3 		$3.75M Buy
23,234
+7,258
+45% +$992K 0.01% 1400
2018
Q2 		$2.11M Sell
15,976
-8,334
-34% -$786K ﹤0.01% 1721
2018
Q1 		$1.8M Sell
24,310
-43
-0.2% -$2.87K ﹤0.01% 1766
2017
Q4 		$1.35M Sell
24,353
-528
-2% -$28K ﹤0.01% 1952
2017
Q3 		$1.13M Buy
24,881
+14,341
+136% +$573K ﹤0.01% 2024
2017
Q2 		$355K Buy
10,540
+3,222
+44% +$105K ﹤0.01% 2622
2017
Q1 		$217K Sell
7,318
-2,861
-28% -$88.5K ﹤0.01% 2889
2016
Q4 		$279K Sell
10,179
-11,244
-52% -$452K ﹤0.01% 2668
2016
Q3 		$1.32M Buy
21,423
+6,272
+41% +$190K ﹤0.01% 1709
2016
Q2 		$289K Buy
15,151
+2,300
+18% +$42.6K ﹤0.01% 2428
2016
Q1 		$251K Buy
12,851
+765
+6% +$13.4K ﹤0.01% 2450
2015
Q4 		$466K Buy
12,086
+550
+5% +$17.8K ﹤0.01% 2020
2015
Q3 		$370K Buy
11,536
+1,004
+10% +$34.1K ﹤0.01% 2058
2015
Q2 		$320K Buy
+10,532
New +$215K ﹤0.01% 2255
2015
Q1 		– Sell
-16,697
Closed -$242K – 2400
2014
Q4 		$242K Buy
16,697
+3,275
+24% +$55.5K ﹤0.01% 2180
2014
Q3 		$283K Hold
13,422
– – ﹤0.01% 2056
2014
Q2 		$400K Buy
13,422
+3,394
+34% +$107K ﹤0.01% 1940
2014
Q1 		$241K Buy
+10,028
New +$256K ﹤0.01% 2031
2013
Q4 		– Sell
-33,822
Closed -$1.6M – 2027
2013
Q3 		$1.6M Sell
33,822
-26,139
-44% -$1.01M 0.01% 990
2013
Q2 		$2.28M Buy
+59,961
New +$2.14M 0.02% 744

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Raymond James & Associates's SRPT Position: Q3 2024 in Review

Raymond James & Associates increased its Sarepta Therapeutics (SRPT) stake by 19% in Q3 2024, buying an estimated $562K and bringing the position to 25,713 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1928.

Raymond James & Associates first reported a position in SRPT in Q2 2013 and has held it in 44 quarters since. The position peaked at $6.13M in Q4 2020. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Raymond James & Associates held 25,713 shares of Sarepta Therapeutics worth $3.21M as of Q3 2024.
  • Raymond James & Associates bought 4,065 Sarepta Therapeutics shares in Q3 2024, an estimated $562K.
  • Sarepta Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1928 holding.
  • Raymond James & Associates first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 44 quarters since.
  • Raymond James & Associates's Sarepta Therapeutics position peaked at $6.13M in Q4 2020.
  • 457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.